Aileron Therapeutics Inc (ALRN) SEC Filing 8-K Material Event for the period ending Saturday, September 28, 2019

Aileron Therapeutics Inc

CIK: 1420565 Ticker: ALRN

View differences made from one to another to evaluate Aileron Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aileron Therapeutics Inc.


Assess how Aileron Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aileron Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: ALRN
CIK: 1420565
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-258919
Submitted to the SEC: Mon Sep 30 2019 5:07:06 PM EST
Accepted by the SEC: Mon Sep 30 2019
Period: Saturday, September 28, 2019
Industry: Pharmaceutical Preparations
  1. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: